Regenerative medicine company Tengion has appointed John L. Miclot as president and chief executive officer. Most recently, Miclot was an executive-in-residence at Warburg Pincus. He was president and chief executive officer of CCS Medical, a company owned by Warburg Pincus from 2008 until completion of a financial restructuring of the company in 2010.
Tengion, a leader in regenerative medicine, today announced the appointment of John L. Miclot as its President and Chief Executive Officer. Most recently, Mr. Miclot was an Executive-in-Residence at Warburg Pincus. He was President and Chief Executive Officer of CCS Medical, Inc., a company owned by Warburg Pincus and a provider of products and services for patients with chronic diseases, from 2008 until completion of a financial restructuring of the company in 2010. From 2003 to 2008, Mr. Miclot served as President and Chief Executive Officer of Respironics, Inc., where he developed and implemented a growth strategy that resulted in sale of the company for $5.1 billion to Royal Philips.
David I. Scheer, Chairman of the Board of Directors of Tengion said, “John’s proven track record of driving company growth and realizing shareholder value make him an ideal choice to lead Tengion. As we continue to pursue strategic partnership and financing discussions, his experience will be invaluable and we look forward to working with him to achieve key Tengion milestones in 2012.”
“Tengion’s pipeline of programs has shown significant promise and potential,” said Mr. Miclot. “With an initial clinical trial for the Neo-Urinary Conduit currently ongoing and a preclinical Neo-Kidney Augment program advancing, this is an exciting time to join and a pivotal time for the Company. My goal is to work with and lead the team to achieve the full potential of these programs and Tengion’s Organ Regeneration Platform.”
Mr. Miclot brings nearly 25 years of healthcare industry experience and leadership to Tengion. Prior to leading CCS Medical, Mr. Miclot served as Chief Executive Officer of Philips Home Healthcare Solutions following the acquisition of Respironics, Inc. by Royal Philips. Mr. Miclot spent 10 years in senior roles at Respironics, ultimately serving as President and Chief Executive Officer from 2003 to 2008. While in that role, Mr. Miclot led Respironics to record annual revenues of more than $1 billion. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies, Inc., a medical device company. Mr. Miclot served in various positions at Healthdyne from 1995 to 1998, including Senior Vice President, Sales and Marketing. Earlier in his career, he held sales and marketing roles at Medex, Ohmeda, Baxter Edwards, and DeRoyal Industries. Mr. Miclot is a director of Wright Medical Group, Inc. and Dentsply International Inc., and serves as Chairman of the Board of Directors of Breathe Technologies, Inc. He is also a director of the Pittsburgh Zoo & PPG Aquarium and Burger King Cancer Caring Center. He earned his B.B.A. in marketing from the University of Iowa.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform(TM) that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit(TM), an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical candidate is the Neo-Kidney Augment(TM), which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion’s Neo-Bladder Augment(TM) for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.